SE9900100D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE9900100D0
SE9900100D0 SE9900100A SE9900100A SE9900100D0 SE 9900100 D0 SE9900100 D0 SE 9900100D0 SE 9900100 A SE9900100 A SE 9900100A SE 9900100 A SE9900100 A SE 9900100A SE 9900100 D0 SE9900100 D0 SE 9900100D0
Authority
SE
Sweden
Prior art keywords
new compounds
sub
compounds
psychotic
formula
Prior art date
Application number
SE9900100A
Other languages
English (en)
Swedish (sv)
Inventor
Iii James T Loch
George Mullen
Eifion Phillips
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9900100A priority Critical patent/SE9900100D0/xx
Publication of SE9900100D0 publication Critical patent/SE9900100D0/xx
Priority to AU23343/00A priority patent/AU775433B2/en
Priority to ES99967044T priority patent/ES2200590T3/es
Priority to CN998164224A priority patent/CN1132837C/zh
Priority to HU0200513A priority patent/HUP0200513A3/hu
Priority to DE69908185T priority patent/DE69908185T2/de
Priority to BR9916906-1A priority patent/BR9916906A/pt
Priority to DK99967044T priority patent/DK1147114T3/da
Priority to KR1020017008939A priority patent/KR100660496B1/ko
Priority to AT99967044T priority patent/ATE240960T1/de
Priority to EEP200100370A priority patent/EE04528B1/xx
Priority to IL14426699A priority patent/IL144266A0/xx
Priority to UA2001085777A priority patent/UA71598C2/uk
Priority to SI9930375T priority patent/SI1147114T1/xx
Priority to CZ20012554A priority patent/CZ20012554A3/cs
Priority to PCT/SE1999/002478 priority patent/WO2000042044A1/en
Priority to CA002359990A priority patent/CA2359990A1/en
Priority to NZ512733A priority patent/NZ512733A/en
Priority to HK02102161.7A priority patent/HK1040517B/en
Priority to PT99967044T priority patent/PT1147114E/pt
Priority to EP99967044A priority patent/EP1147114B1/de
Priority to RU2001122812/04A priority patent/RU2233282C2/ru
Priority to US09/529,654 priority patent/US6995167B2/en
Priority to TR2001/02042T priority patent/TR200102042T2/xx
Priority to IDW00200101529A priority patent/ID30034A/id
Priority to JP2000593611A priority patent/JP2002534525A/ja
Priority to SK993-2001A priority patent/SK9932001A3/sk
Priority to MYPI20000100A priority patent/MY118109A/en
Priority to ARP000100156A priority patent/AR022283A1/es
Priority to TW089100989A priority patent/TWI227237B/zh
Priority to TW093106537A priority patent/TW200413387A/zh
Priority to SA00200987A priority patent/SA00200987B1/ar
Priority to ZA200105527A priority patent/ZA200105527B/en
Priority to IS6000A priority patent/IS6000A/is
Priority to NO20013478A priority patent/NO20013478L/no
Priority to US11/181,098 priority patent/US7196096B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SE9900100A 1999-01-15 1999-01-15 New compounds SE9900100D0 (sv)

Priority Applications (36)

Application Number Priority Date Filing Date Title
SE9900100A SE9900100D0 (sv) 1999-01-15 1999-01-15 New compounds
SK993-2001A SK9932001A3 (en) 1999-01-15 1999-12-23 Novel aralkyl amines of spirofuropyridines useful in therapy
CA002359990A CA2359990A1 (en) 1999-01-15 1999-12-23 Novel aralkyl amines of spirofuropyridines useful in therapy
NZ512733A NZ512733A (en) 1999-01-15 1999-12-23 Aralkyl amines of spirofuropyridines useful in treating psychotic and intellectual impairment disorders
CN998164224A CN1132837C (zh) 1999-01-15 1999-12-23 螺呋喃并吡啶芳烷基胺、其制法和中间体及其药物组合物和制药用途
HU0200513A HUP0200513A3 (en) 1999-01-15 1999-12-23 Novel aralkyl amines of spirofuropyridines useful in therapy, process for their preparation, pharmaceutical compositions containing them and their use
DE69908185T DE69908185T2 (de) 1999-01-15 1999-12-23 Therapeutisch nützliche arylalkylamine von spirofuropyridinen
BR9916906-1A BR9916906A (pt) 1999-01-15 1999-12-23 Composto, composição farmacêutica, uso de umcomposto, métodos de tratamento ou profilaxiade, distúrbios psicóticos ou distúrbios deenfraquecimento intelectual, e de tratamento ouprofilaxia de doenças ou condições humanas emque a ativação do receptor alfa-7 nicotìnico ébenéfica, e, processo para preparar um composto
DK99967044T DK1147114T3 (da) 1999-01-15 1999-12-23 Hidtil ukendt aralkylaminer af spirofuropyridiner, der er egnede til terapi
KR1020017008939A KR100660496B1 (ko) 1999-01-15 1999-12-23 치료에 유용한 스피로푸로피리딘의 신규 아랄킬 아민
AT99967044T ATE240960T1 (de) 1999-01-15 1999-12-23 Therapeutisch nützliche arylalkylamine von spirofuropyridinen
EEP200100370A EE04528B1 (et) 1999-01-15 1999-12-23 Teraapias kasutatavad spirofuropridiinide aralklamiinid
IL14426699A IL144266A0 (en) 1999-01-15 1999-12-23 Novel aralkyl amines of spirofuropyridines useful in therapy
UA2001085777A UA71598C2 (en) 1999-01-15 1999-12-23 Furopiridines aralkilamines, a pharmaceutical composition based thereon, a method for the preparation thereof and furopiridine derivatives
SI9930375T SI1147114T1 (en) 1999-01-15 1999-12-23 Novel aralkyl amines of spirofuropyridines useful in therapy
CZ20012554A CZ20012554A3 (cs) 1999-01-15 1999-12-23 Nové aralkylaminy spirofuropyridinů vhodné pro léčení
PCT/SE1999/002478 WO2000042044A1 (en) 1999-01-15 1999-12-23 Novel aralkyl amines of spirofuropyridines useful in therapy
AU23343/00A AU775433B2 (en) 1999-01-15 1999-12-23 Novel aralkyl amines of spirofuropyridines useful in therapy
HK02102161.7A HK1040517B (en) 1999-01-15 1999-12-23 New spirofuropyridine aralkylamines useful in therapy
ES99967044T ES2200590T3 (es) 1999-01-15 1999-12-23 Nuevas aralquilaminas de espirofuropiridinas utiles en terapia.
PT99967044T PT1147114E (pt) 1999-01-15 1999-12-23 Novos aralquilaminas de espirofuropiridinas uteis em terapia.
EP99967044A EP1147114B1 (de) 1999-01-15 1999-12-23 Therapeutisch nützliche arylalkylamine von spirofuropyridinen
RU2001122812/04A RU2233282C2 (ru) 1999-01-15 1999-12-23 Аралкиламины фуропиридинов, способ их получения, фармацевтическая композиция на их основе и промежуточные вещества
US09/529,654 US6995167B2 (en) 1999-01-15 1999-12-23 Arylkylamine spirofuropyridines useful in therapy
TR2001/02042T TR200102042T2 (tr) 1999-01-15 1999-12-23 Spiro fropiridinlerin, tedavide faydalı yeni aralkil aminleri.
IDW00200101529A ID30034A (id) 1999-01-15 1999-12-23 Aralkil amina baru dari spirofuropiridin yang berguna dalam terapi
JP2000593611A JP2002534525A (ja) 1999-01-15 1999-12-23 治療において有用なスピロフロピリジンの新規なアラルキルアミン
ARP000100156A AR022283A1 (es) 1999-01-15 2000-01-13 Aminas substituidas de espirofuropiridinas novedosas utiles en terapia
MYPI20000100A MY118109A (en) 1999-01-15 2000-01-13 Novel aralkyl amines of spirofuropyridines useful in therapy
TW089100989A TWI227237B (en) 1999-01-15 2000-01-21 Novel aralkyl amines of spirofuropyridines useful in therapy
TW093106537A TW200413387A (en) 1999-01-15 2000-01-21 Novel intermediates for preparing aralkyl amines of spirofuropyridines useful in therapy
SA00200987A SA00200987B1 (ar) 1999-01-15 2000-02-21 Aralkyl Amines جديدة من Spirofuropyridines مفيدة في العلاج
ZA200105527A ZA200105527B (en) 1999-01-15 2001-07-04 Novel aralkyl amines of spirofuropyridines useful in therapy.
IS6000A IS6000A (is) 1999-01-15 2001-07-12 Ný aralkýlamín af spírófúrópýridínum sem nytsamleg eru í meðferð
NO20013478A NO20013478L (no) 1999-01-15 2001-07-13 Nye aralkylaminer av spirofuropyridiner som er nyttige i terapi
US11/181,098 US7196096B2 (en) 1999-01-15 2005-07-14 Substituted amines of spirofuropyridines useful in therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900100A SE9900100D0 (sv) 1999-01-15 1999-01-15 New compounds

Publications (1)

Publication Number Publication Date
SE9900100D0 true SE9900100D0 (sv) 1999-01-15

Family

ID=20414101

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9900100A SE9900100D0 (sv) 1999-01-15 1999-01-15 New compounds

Country Status (34)

Country Link
US (2) US6995167B2 (de)
EP (1) EP1147114B1 (de)
JP (1) JP2002534525A (de)
KR (1) KR100660496B1 (de)
CN (1) CN1132837C (de)
AR (1) AR022283A1 (de)
AT (1) ATE240960T1 (de)
AU (1) AU775433B2 (de)
BR (1) BR9916906A (de)
CA (1) CA2359990A1 (de)
CZ (1) CZ20012554A3 (de)
DE (1) DE69908185T2 (de)
DK (1) DK1147114T3 (de)
EE (1) EE04528B1 (de)
ES (1) ES2200590T3 (de)
HK (1) HK1040517B (de)
HU (1) HUP0200513A3 (de)
ID (1) ID30034A (de)
IL (1) IL144266A0 (de)
IS (1) IS6000A (de)
MY (1) MY118109A (de)
NO (1) NO20013478L (de)
NZ (1) NZ512733A (de)
PT (1) PT1147114E (de)
RU (1) RU2233282C2 (de)
SA (1) SA00200987B1 (de)
SE (1) SE9900100D0 (de)
SI (1) SI1147114T1 (de)
SK (1) SK9932001A3 (de)
TR (1) TR200102042T2 (de)
TW (2) TWI227237B (de)
UA (1) UA71598C2 (de)
WO (1) WO2000042044A1 (de)
ZA (1) ZA200105527B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) * 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
WO2002096912A1 (en) * 2001-06-01 2002-12-05 Astrazeneca Ab Novel ligand for nicotinic acetylcholine receptors useful in therapy
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
CZ2004408A3 (cs) 2001-10-02 2005-03-16 Pharmacia & Upjohn Company Azabicyklicky substituované kondenzované heteroarylsloučeniny
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
JP4523775B2 (ja) 2002-04-18 2010-08-11 アストラゼネカ・アクチエボラーグ 複素環化合物
BR0309343A (pt) * 2002-04-18 2005-02-15 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0309342A (pt) 2002-04-18 2005-02-15 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
US7244745B2 (en) 2002-08-30 2007-07-17 Memory Pharmaceuticals Corp. Heterocyclic compounds, methods for the preparation thereof, and uses thereof
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
CA2499128C (en) 2002-09-25 2012-07-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
ATE378048T1 (de) * 2002-12-06 2007-11-15 The Feinstein Inst Medical Res Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
CN100355756C (zh) * 2003-01-08 2007-12-19 三菱制药株式会社 精神分裂症的治疗剂
US20050129610A1 (en) * 2003-06-24 2005-06-16 Johns Hopkins University Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor
JP4855264B2 (ja) * 2003-10-21 2012-01-18 アストラゼネカ・アクチエボラーグ スピロフロピリジンアリール誘導体
US7045530B2 (en) 2003-12-22 2006-05-16 Abbott Laboratories Spirocyclic quinuclidinic ether derivatives
WO2005092890A2 (en) 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
RU2448111C2 (ru) * 2006-08-21 2012-04-20 Дженентек, Инк. Соединения азабензофуранила и способ их применения
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CA2728675A1 (en) 2008-06-20 2009-12-23 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
HRP20150882T1 (hr) 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
HUE026815T2 (en) 2008-11-19 2016-07-28 Forum Pharmaceuticals Inc Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
AU2010247835A1 (en) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
KR20150002794A (ko) 2012-04-12 2015-01-07 제논 파마슈티칼스 인크. 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
US9593106B2 (en) 2013-02-07 2017-03-14 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
JP6401254B2 (ja) 2013-06-21 2018-10-10 武田薬品工業株式会社 プロキネシチン受容体のモジュレータとしての１−スルホニルピペリジン誘導体
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
WO2017218920A1 (en) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Asymmetric synthesis of funapide
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
GB202414193D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414197D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE122353T1 (de) * 1987-10-05 1995-05-15 Yamanouchi Pharma Co Ltd Heterozyklische spiroverbindungen und ihre herstellung.
JPH0195922A (ja) 1987-10-08 1989-04-14 Mazda Motor Corp 車両のサスペンション制御装置
SU1540240A1 (ru) * 1988-05-16 1995-09-10 Институт Тонкой Органической Химии Им.А.Л.Мнджояна 5-ЗАМЕЩЕННЫЕ 1-АМИНО -8,9-ДИГИДРО -8,8-ДИМЕТИЛ-3, 6Н- ПИРАЗОЛО [3,4-B] ПИРАНО[[4′,3′-d]] ПИРИДИНА ИЛИ ИХ ГИДРОХЛОРИДЫ, ОБЛАДАЮЩИЕ ПРОТИВОСУДОРОЖНОЙ АКТИВНОСТЬЮ
JP3708962B2 (ja) * 1994-08-24 2005-10-19 アストラゼネカ・アクチエボラーグ 治療に有用なスピロ−アザ二環式化合物
DE69612292T2 (de) 1995-07-28 2001-11-22 Abbott Laboratories, Abbott Park Furo-, thieno- und pyrrolopyridine und verwandte pyrinidin-, pyridazin- und triazinverbindungen verwendbar zur kontrolle von chemische synaptische übertragung
US6156783A (en) * 1996-04-30 2000-12-05 Smithkline Beecham P.L.C. Spiroazabicyclic compounds, processes for their preparation, and their pharmaceutical use
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds

Also Published As

Publication number Publication date
UA71598C2 (en) 2004-12-15
IL144266A0 (en) 2002-05-23
TR200102042T2 (tr) 2002-05-21
SI1147114T1 (en) 2003-12-31
AR022283A1 (es) 2002-09-04
ZA200105527B (en) 2002-10-04
NZ512733A (en) 2003-08-29
CN1337964A (zh) 2002-02-27
KR100660496B1 (ko) 2006-12-22
TW200413387A (en) 2004-08-01
AU2334300A (en) 2000-08-01
NO20013478D0 (no) 2001-07-13
DK1147114T3 (da) 2003-09-15
US20030149065A1 (en) 2003-08-07
ID30034A (id) 2001-11-01
KR20010086167A (ko) 2001-09-08
HK1040517A1 (en) 2002-06-14
AU775433B2 (en) 2004-07-29
HK1040517B (en) 2003-09-05
ES2200590T3 (es) 2004-03-01
RU2233282C2 (ru) 2004-07-27
EP1147114A1 (de) 2001-10-24
CN1132837C (zh) 2003-12-31
US7196096B2 (en) 2007-03-27
US20050250802A1 (en) 2005-11-10
BR9916906A (pt) 2001-10-30
EE200100370A (et) 2002-10-15
CA2359990A1 (en) 2000-07-20
PT1147114E (pt) 2003-10-31
SA00200987B1 (ar) 2006-11-07
CZ20012554A3 (cs) 2002-01-16
DE69908185D1 (de) 2003-06-26
TWI227237B (en) 2005-02-01
EP1147114B1 (de) 2003-05-21
SK9932001A3 (en) 2002-04-04
HUP0200513A2 (en) 2002-06-29
WO2000042044A1 (en) 2000-07-20
HUP0200513A3 (en) 2004-07-28
US6995167B2 (en) 2006-02-07
ATE240960T1 (de) 2003-06-15
EE04528B1 (et) 2005-08-15
NO20013478L (no) 2001-09-14
IS6000A (is) 2001-07-12
JP2002534525A (ja) 2002-10-15
MY118109A (en) 2004-08-30
DE69908185T2 (de) 2004-06-03

Similar Documents

Publication Publication Date Title
SE9903760D0 (sv) New compounds
GB9801690D0 (en) Therapeutic agents
IS7857A (is) Setnar pýrróló-pýrasól afleiður sem kínasa hindrar
DK1112106T3 (da) Serotonerge 5HT2-agonister til behandling af glaukom
AU2002246728A1 (en) Carboline derivatives
SE9904176D0 (sv) New use
ATE305788T1 (de) (s,s)-reboxetin zur behandlung von inkontinenz
DK1204654T3 (da) Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister
GB9929552D0 (en) Compounds
DE60216233D1 (en) Carbolinderivate
MXPA03002911A (es) Compuestos quimicos.
AU2001266575A1 (en) Chemical compounds
MXPA02012076A (es) Compuestos quimicos.
GB0114185D0 (en) Compounds
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
BRPI0409376A (pt) derivados de indeno como agentes farmacêuticos
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
ATE417856T1 (de) Motilidverbindungen
DE60112960D1 (de) Kondensierte pyridoindolderivate
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
PT1204659E (pt) Benzofuranos serotoninergicos
ATE259813T1 (de) Triazolopyrimidinderivate